BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NanoValent Pharmaceuticals Acquires Targesome, Inc. Intellectual Property


1/10/2008 1:28:33 PM

Nanovalent Pharmaceuticals Inc. of Bozeman, Montana has acquired the Targesome intellectual property portfolio. The portfolio consists of eleven patents covering the utilization of polymerized nanoparticles for drug delivery and imaging purposes. Extensive research by Nanovalent attorneys indicate that these patents mark the earliest prior art related to delivery of pharmaceuticals, nucleic acids, and imaging agents using polymerized nanoparticles.

Financial terms of the transaction were not disclosed. Dr. James C. Hamilton, co-founder and president of NanoValent stated, “Securing this family of patents represents achievement of a critical milestone in our intellectual property strategy, and adds significantly to NanoValent’s growing patent portfolio. This should give NanoValent freedom to operate within our domain of polymerized liposomal nanoparticle drug delivery.”

NanoValent is commercializing the Polymerized Liposomal Nanoparticle (PLN) drug delivery platform. The Firm provides custom drug delivery services to private pharmaceutical and academic organizations. NanoValent is currently using proceeds from its custom drug delivery service business to drive three internal development programs. These include a PLN vaccine against Yersinia pestis (NANO-VX), SN38 loaded PLNs to treat Ewing’s Sarcoma (NANO-01), and drug loaded PLNs to treat pediatric Acute Lymphoblastic Leukemia (NANO-03).



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES